{"id":2697,"date":"2026-06-16T14:36:56","date_gmt":"2026-06-16T14:36:56","guid":{"rendered":"https:\/\/gesmd.es\/?page_id=2697"},"modified":"2026-06-26T11:18:09","modified_gmt":"2026-06-26T11:18:09","slug":"proyectos-en-curso","status":"publish","type":"page","link":"https:\/\/gesmd.es\/?page_id=2697","title":{"rendered":"PROYECTOS EN CURSO"},"content":{"rendered":"\n
\n

Proyectos en curso<\/h1><\/div>\n<\/div>\n\n\n\n
\n

EZH2 Molecular Alterations Drive Micromegakaryocyte Expansion in MDS Defining a Specific High-Risk Group<\/h4><\/div>\n\n\n\n

Investigador principal: <\/strong>Silvia Saumell, Hospital Universitario Vall d’Hebron
Email<\/strong>: silvia.saumell.tutusaus@hmar.cat<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

An\u00e1lisis de las mutaciones del gen LNK\/SH2B3 en los pacientes con s\u00edndrome mielodispl\u00e1sico (SMD)<\/h4><\/div>\n\n\n\n

Investigador principal: <\/strong>Julia Montoro, Hospital Universitario Vall d’Hebron
Email<\/strong>:<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

\u00bfLas c\u00e9lulas mesenquimales forman parte del clon tumoral en los S\u00edndromes Mielodispl\u00e1sicos?<\/h4><\/div>\n\n\n\n

Investigador principal: <\/strong>M\u00f3nica del Rey, Hospital Cl\u00ednico Universitario de Salamanca
Email<\/strong>:<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

SMD con RUNX1 mutado y haploinsuficiencia de EZH2 (EZH2mut o (-7\/del(7q))<\/h4><\/div>\n\n\n\n

Investigador principal: <\/strong>Silvia Saumell, Hospital Universitario Vall d’Hebron
Email<\/strong>: silvia.saumell.tutusaus@hmar.cat<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Disecci\u00f3n del microambiente inmune en los SMD<\/h4><\/div>\n\n\n\n

Investigador principal: <\/strong>Irene Ga\u00f1\u00e1n, Cl\u00ednica Universidad de Navarra
Email<\/strong>: iganangomez@unav.es<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Estudio del Papel del Nicho de M\u00e9dula \u00d3sea en la Deficiencia de GATA2 (BMN-G2D)<\/h4><\/div>\n\n\n\n

Investigador principal: <\/strong>Alessandra Giorgetti, IDIBELL Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge
Email<\/strong>: agiorgetti@idibell.cat<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Caracterizaci\u00f3n del paisaje germinal y som\u00e1tico de las neoplasias mieloides asociadas a tratamiento (NMRT) y los sindromes mielodispl\u00e1sicos en pacientes menores de 50 a\u00f1os<\/h4><\/div>\n\n\n\n

Investigador principal: <\/strong>Francesc Sol\u00e9; Julia Mestre, Institut de Recerca contra la Leuc\u00e8mia Josep Carreras
Email<\/strong>:<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Marcadores gen\u00e9ticos caracter\u00edsticos de la LMMC agudizada<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Marta Cabez\u00f3n, Hospital Universitario Germans Trias i Pujol
Email<\/strong>: mcabezon@iconcologia.net<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Pron\u00f3stico de los pacientes con SMD con mutaci\u00f3n en SF3B1. Importancia del tipo de mutaci\u00f3n en la supervivencia y en el riesgo de progresi\u00f3n<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Jos\u00e9 Francisco Falantes, Hospital Universitario Virgen del Roc\u00edo
Email<\/strong>:<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Inflamaci\u00f3n en S\u00edndromes mielodispl\u00e1sicos: Papel de los macr\u00f3fagos y potencial terap\u00e9utico de las mesenquimales<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Sandra Munti\u00f3n, Hospital Cl\u00ednico Universitario de Salamanca
Email<\/strong>:<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Fibrosis Medular en S\u00edndromes Mielodispl\u00e1sicos y Leucemias Agudas Mieloides: Mecanismos Patogen\u00e9ticos<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Teresa Bernal, Hospital Universitario Central de Asturias
Email<\/strong>: bernalmaria@uniovi.es<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Asociaci\u00f3n de la Hematopoyesis Clonal y la Disgranulopoyesis en Portadores de Mutaciones Germinales en ETV6 Sin Neoplasias Hematol\u00f3gicas<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Sara Torres, Hospital Universitario Vall d’Hebron
Email<\/strong>:<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Neoplasia mieloide DDX41. Propuesta de recogida de casos a nivel nacional<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Carolina Martinez Laperche, Hospital General Universitario Gregorio Mara\u00f1\u00f3n
Email<\/strong>:<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

UMBRELLA-SUMMA: Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling personalized genoMic Medicine in public heAlth system<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Mar\u00eda D\u00edez Campelo, Hospital Universitario de Salamanca. Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL)
Email<\/strong>:<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

UMBRELLA-SUMMA Legacy: Unified platforM for a Better integRal Evaluation of myeLodyspLastic syndromes in spAin-Strategy for Unraveling personalized genoMic Medicine in public heAlth system incorporating patient reported outcomes<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Mar\u00eda D\u00edez Campelo, Hospital Universitario de Salamanca. Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL)
Email<\/strong>:<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Quantum Synthetic Data Generation for in silico clinical trials (QSynthInSilico)<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Mikel Hern\u00e1ez, CIMA \u2013 Universidad de Navarra
Email<\/strong>:<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Trasfusi\u00f3n y S\u00edndromes Mielodispl\u00e1sicos (SMD). Factores Predictivos de Adecuaci\u00f3n de la Trasfusi\u00f3n de Concentrados de Hemat\u00edes en SMD de Bajo Riesgo<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Teresa Bernal, Hospital Universitario Central de Asturias
Email<\/strong>: bernalmaria@uniovi.es<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Ama Low Risk Project<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Francesc Sol\u00e9, Institut de Recerca contra la Leuc\u00e8mia Josep Carreras
Email<\/strong>: <\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

SMD cariotipo normal \/ sin mitosis<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Francesc Sol\u00e9, Institut de Recerca contra la Leuc\u00e8mia Josep Carreras
Email<\/strong>: <\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Frailty Evaluation in Patients with Myelodysplastic Syndrome Candidates for Treatment. Multicenter and Prospective Study on Behalf of the GESMD<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Mar\u00eda Queralt Salas, Hospital Cl\u00ednic de Barcelona
Email<\/strong>: <\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Caracterizaci\u00f3n cl\u00ednica y biol\u00f3gica de las neoplasias mielodispl\u00e1sicas relacionadas con la radioterapia<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Julia Montoro, Hospital Universitario Vall d’Hebron
Email<\/strong>: jmontoro@vhio.net<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Caracterizaci\u00f3n de variantes estructurales germinales mediante secuenciaci\u00f3n de genoma completo (WGS) en pacientes con leucemia mielomonoc\u00edtica cr\u00f3nica de inicio temprano<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Francisco Beas, Hospital Universitario Vall d’Hebron
Email<\/strong>: franciscobeas@vhio.net<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

S\u00edndromes mielodispl\u00e1sicos con deleci\u00f3n 7q: incidencia y valor pron\u00f3stico de las deleciones del gen EZH2 y de las mutaciones gen\u00e9ticas<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Iv\u00e1n Mart\u00edn, Instituto de Investigaci\u00f3n sanitaria INCLIVA
Email<\/strong>: imartin@incliva.es<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

P\u00e9rdida de la respuesta inflamatoria en la patog\u00e9nesis y el abordaje terap\u00e9utico de los s\u00edndromes mielodispl\u00e1sicos<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Teresa Ezponda, CIMA Universidad de Navarra
Email<\/strong>: tezponda@unav.es<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Modelado y caracterizaci\u00f3n de jerarqu\u00edas hematopoy\u00e9ticas granulo-monoc\u00edticas en los s\u00edndromes mielodispl\u00e1sicos<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Irene Ga\u00f1\u00e1n, Cl\u00ednica Universidad de Navarra
Email<\/strong>: iganangomez@unav.es<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Impacto de las mutaciones driver (JAK2\/CALR\/MPL) en el fenotipo y pron\u00f3stico de pacientes con SMD y mutaci\u00f3n SF3B1: del s\u00edndrome mielodispl\u00e1sico al solapamiento SMD\/NMPc. Estudio multic\u00e9ntrico del GESMD<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Jos\u00e9 Antonio Farah, Hospital Cl\u00ednico Universitario de Santiago de Compostela
Email<\/strong>: jose.antonio.farah.gamarra@sergas.es<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Implicaciones moleculares de la duplicaci\u00f3n parcial en t\u00e1ndem del gen MLL (MLL-PTD) en el s\u00edndrome mielodispl\u00e1sico (SMD): mecanismos, impacto funcional y relevancia cl\u00ednica<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Sara Montolio, Hospital Universitario Son Espases, Palma de Mallorca
Email<\/strong>: saramontolio5@gmail.com<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Evaluaci\u00f3n de marcadores inflamatorios como predictores pron\u00f3sticos en leucemia mielomonoc\u00edtica cr\u00f3nica<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Tomas Rivero; Blanca Xicoy, Institut Catal\u00e0 d’ Oncolog\u00eda, Badalona, Espa
Email<\/strong>: triveroe@iconcologia.net<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Reclasificaci\u00f3n pron\u00f3stica y terap\u00e9utica con modelo AIPSS-MDS de los SMD SF3B1 seg\u00fan OMS 2022<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Raquel de Paz, Hospital Universitario la Paz
Email<\/strong>: depazraquel@gmail.com<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

S\u00edndrome VEXAS con variantes no can\u00f3nicas del gen UBA1: caracterizaci\u00f3n cl\u00ednica, respuesta terap\u00e9utica y papel de la enfermedad residual medible<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Marina Diaz, Hospital Clinic Barcelona
Email<\/strong>: diazbeya@clinic.cat<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Supervivencia global en pacientes con s\u00edndrome mielodispl\u00e1sico con sideroblastos en anillo: Comparaci\u00f3n con la poblaci\u00f3n general espa\u00f1ola ajustada por edad y sex<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Gabriela G\u00e1lvez Zavala; Ana Alfonso, Cl\u00ednica Universidad de Navarra
Email<\/strong>: ggalvezz@unav.es<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

HMA\/VEN como puente al TPH en pacientes con SMD y LMMC de alto riesgo<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Marina D\u00edaz Beya, Hospital Clinic Barcelona
Email<\/strong>: diazbeya@clinic.cat<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

Temporal Trends in Overall Survival Among Patients with High-Risk MDS: Insights from the Spanish MDS Registry (RESMD)<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Ana Alfonso, Cl\u00ednica Universidad de Navarra
Email<\/strong>:<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n

LMMC con mutaciones en v\u00edas de se\u00f1alizaci\u00f3n (BRAF)<\/h4><\/div>\n\n\n\n

Investigador principal:<\/strong> Paula Salcedo, ICO Badalona
Email<\/strong>:<\/p>\n\n\n\n

\n
Ver proyecto<\/div><\/path><\/svg><\/span><\/a><\/div><\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Proyectos en curso EZH2 Molecular Alterations Drive Micromegakaryocyte Expansion in MDS Defining a Specific High-Risk Group Investigador principal: Silvia Saumell, […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-2697","page","type-page","status-publish","hentry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"gesmd.jc.alvarez@ene.es","author_link":"https:\/\/gesmd.es\/?author=1"},"uagb_comment_info":0,"uagb_excerpt":"Proyectos en curso EZH2 Molecular Alterations Drive Micromegakaryocyte Expansion in MDS Defining a Specific High-Risk Group Investigador principal: Silvia Saumell, […]","_links":{"self":[{"href":"https:\/\/gesmd.es\/index.php?rest_route=\/wp\/v2\/pages\/2697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gesmd.es\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/gesmd.es\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/gesmd.es\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/gesmd.es\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2697"}],"version-history":[{"count":63,"href":"https:\/\/gesmd.es\/index.php?rest_route=\/wp\/v2\/pages\/2697\/revisions"}],"predecessor-version":[{"id":3565,"href":"https:\/\/gesmd.es\/index.php?rest_route=\/wp\/v2\/pages\/2697\/revisions\/3565"}],"wp:attachment":[{"href":"https:\/\/gesmd.es\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}